EPICS: Global Perspectives in CAR T and Bispecific Agents in Hematologic Malignancies 2022
Latest therapeutic developments in CAR T and bispecific agents in hematologic malignancies
Faculty Co-Chair
Frederick Locke, MD
H. Lee Moffitt Cancer Center, Tampa, FL, USA
Faculty Co-Chair
Marie José Kersten, MD
Amsterdam UMC, Amsterdam, the Netherlands
Faculty Members
Keith Stewart, MBChB, MBA
University Health Network, Toronto, Canada
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Paolo Caimi, MD
Case Western Reserve University School of Medicine, Cleveland, OH, USA
Peter Martin, MD
Weill Cornell Medicine, New York, NY, USA
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, USA
Olivier Tournilhac, MD, PhD
Clermont Auvergne University, Clermont-Ferrand, France
Josep-Maria Ribera, MD, PhD
Hospital Germans Trias i Pujol, Barcelona, Spain
Paolo Corradini, MD
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Bologna, Italy
REPORT TOPICS INCLUDE
- Update on CAR T in DLBCL
- Update on CAR T in Indolent NHL/MCL
- Update on Bispecific Antibodies in B-NHL
- Update on CAR T in Leukemias
- Update on Bispecific Antibodies in Leukemias
- Update on CAR T in MM
- Update on Bispecific Antibodies in MM
- Impact of Real-world Data on CAR T-Cell Therapies and Bispecific Antibodies
- Sharing Experiences: Current Barriers to Real-world CAR T Adoption in the US
- Sharing Experiences: Current Barriers to Real-world CAR T Adoption in Europe
